On March 9, 2022 Tyligand Bioscience, a clinical-stage biotechnology company focused on developing innovative therapies against drug resistant cancers, reported that the first subject had been dosed in US in a phase 1 trial for its innovative multi-kinase inhibitor TSN084 (Press release, Tyligand Bioscience, MAR 9, 2022, View Source [SID1234644989]). The study includes a dose escalation and dose expansion phase to evaluate the safety, tolerability, and preliminary anti-tumor activity in subjects with advanced or metastatic malignancies, to be conducted both in US and China. The first enrollment was led by Dr. Siqing Fu, Professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, Houston, TX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented: "TSN084 is the front runner of the Tyligand pipeline of innovative molecules. It hits a unique combination of kinase targets including CDK8/19 and offers the possibility of synergistic attack against cancers at multiple fronts. We are glad that it has reached this major milestone in a journey toward becoming a drug that can help patients. We appreciate the dedication of our team members, collaborators and clinical investigators for propelling the project forward with impressive quality and speed."